IDiyas

For the Inventor, By the Inventor

Sakai, Japan

Kazuaki Kitano

USPTO Granted Patents = 12

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 44(Granted Patents)


Location History:

  • Osaka, JA (1976)
  • Suita, JA (1978)
  • Sakai, JP (1980 - 1997)
  • Osaka, JP (1993 - 1999)

Company Filing History:

goldMedal12 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents

Years Active: 1976-1999

Loading Chart...
12 patents (USPTO):Explore Patents
1. 5885979 - N-containing condensed heterocyclic compounds, their production, and (1999-03-23),
2. 5726306 - 4,1-benzoxazepin derivatives and their use (1998-03-10),
3. 5624917 - Method of inhibiting squalene synthetase (1997-04-29),
4. 5543322 - DNA coding for alkaline protease (1996-08-06),
5. 5213980 - Fibroblast growth factor gene transformed hybridoma and enhanced (1993-05-25),
6. 5210029 - Method of producing interleukin-2 (1993-05-11),
7. 4935356 - Production of interleukin-2 (1990-06-19),
8. 4656131 - Method for producing interferons (1987-04-07),
9. 4521340 - Pharmaceutically acceptable salts of the antibiotic C-19393 E.sub.5 (1985-06-04),
10. 4229436 - Antibiotic G-6302 (1980-10-21),
11. 4070244 - Method for producing ubiquinone-10 (1978-01-24),
12. 3979260 - Production of deacetoxycephalosporin C (1976-09-07),

Title: The Innovative Mind of Kazuaki Kitano

Introduction

Kazuaki Kitano, an accomplished inventor based in Sakai, Japan, has made significant contributions to the field of pharmaceuticals. With a total of 12 patents to his name, he is recognized for his innovative approach to developing compounds that target key health issues, including hyperlipidemia and fungal infections.

Latest Patents

Among his latest patents are the groundbreaking N-containing condensed heterocyclic compounds, which are designed to inhibit squalene synthetase and limit fungal growth. These compounds and their salts are proving to be instrumental in treating or preventing hyperlipidemia. Additionally, Kitano has disclosed methods for the production of these vital compounds. Another noteworthy patent involves 4,1-benzoxazepin derivatives, which similarly focus on combating squalene synthetase and fungal proliferation.

Career Highlights

Kazuaki Kitano is associated with Takeda Chemical Industries, Inc., a firm renowned for its commitment to advancing global health through innovative pharmaceuticals. His research and development work has significantly influenced the company's product pipeline and therapeutic strategies.

Collaborations

Throughout his career, Kitano has collaborated with esteemed colleagues such as Shigeru Fujimoto and Ryuichi Tozawa. Together, they have made strides in pharmaceutical research, paving the way for new treatments that address complex medical challenges.

Conclusion

Kazuaki Kitano is a prominent figure in the realm of invention and innovation within the pharmaceutical industry. His extensive patent portfolio reflects his dedication to improving health outcomes through meticulous research and development. As he continues to explore new frontiers in medicine, his work remains vital for future advancements in treating critical health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…